Dr. Carl Friedrich Classen

University Children’s Hospital Rostock, Germany

Email: cfclassen@gmx.de

Qualifications

1989 Ph.D., Luebeck University, pediatrics

Publications (selected)

1. Classen CF, Schulz AS, Sigl-Kraetzig M, Hoffmann GF, Simmonds HA, Fairbanks L, Debatin KM, Friedrich W: Successful HLA-identical bone marrow transplantation in a patient with PNP deficiency using busulfan and fludarabine for conditioning. Bone Marrow Transplant. 2001; 28: 93-96.
2. Classen CF, Schulz AS, Debatin KM, Friedrich W: Severe persistent neuropsychiatric toxicity after an HLA-nonidentical PBSCT (TBI, ALL etoposide, thiotepa) and IL-2-based experimental therapy for poor prognosis relapse. Br J Haematol. 2001; 114: 487-489.
3. Classen CF, Falk CS, Friesen C, Fulda S, Herr I, Debatin KM: NK resistance of a drug-resistant leukemia cell line, mediated by up-regulation of HLA class I expression. Haematologica. 2003; 88: 509-521.
4. Classen, CF, Gnekow A, Debatin KM: Terminal Differentiation of Patient-derived post-TMD Megakaryoblastic AML Cells. Ann Haematol. 2003; 82: 506-510.
5. Classen, CF,  Debatin KM, Friedrich W, Schulz AS: Long-term remission of APL by second allogeneic BMT after CNS relapse following HLA-identical allogeneic BMT. Bone Marrow Transplant. 2003; 32: 843-846.
6. Classen CF, Bird P, Ushmorov A, Debatin KM: The granzyme B inhibitor PI-9 is differentially expressed in all main subtypes of pediatric acute lymphoblastic leukemias Haematologica. 2004; 89: 1316-1323.
7. Classen CF, Behnisch W, Reinhardt D, Koenig M, Moeller P, Debatin KM: Spontaneous complete and sustained remission of a rearrangement CBP (16p13)-positive disseminated congenital myelosarcoma. Ann Hematol. 2005 Apr; 84: 274-5.
8. Classen CF, Teigler-Schlegel A, Röttgers S, Reinhardt D, Döhner K, Debatin KM: AML bearing the translocation t (11;17)(q23;q21): Involvement of MLL and a region close to RARA, with no differentiation response to retinoic acid. Ann Hematol. 2005 Dec; 84: 774-780.
9. Classen CF, Bird P, Debatin KM: Modulation of the granzyme B inhibitor proteinase inhibitor 9 (PI-9) by activation of lymphocytes and monocytes in vitro and by EBV and bacterial infection. Clin Exp Immunol. 2006 Mar; 143(3): 534-42.
10. Classen CF, Warmuth-Metz M, Papke K, Trotter A, Wolff JEA,Wagner S: Late response to radiochemotherapy in pediatric glioblastoma: Report on two patients treated according to HIT-GBM protocols. Ped Hematol Oncol. 2006 Dec; 23(8): 631-7.
11. Schmidt K, Schulz A, Debatin K-M, Friedrich W, Classen CF: CNS Complications in Children Receiving Chemotherapy or Hematopoietic Stem Cell Transplantation: Retrospective Analysis and Clinical Study of Survivors. Pediatr Blood Cancer. 2008 Feb; 50(2): 331-6.
12. Titze U, Janka G, Schneider EM, Prall F, Haffner D, Classen CF: Hemophagocytic lymphohistiocytosis and Kawasaki disease: Combined manifestation and differential diagnosis. Pediatr Blood Cancer. 2009 Sep; 53(3): 493-5.
13. Classen CF, Haffner D, Nizze H, Möller P, Prall F: Endolymphatic non-Langerhans cell histiocytosis of the larynx - Report of an uncommon disease manifestation. J Ped Hematol Oncol. 2010; 32: e173-6.